Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.33 USD | +0.76% | -0.09% | +48.33% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 13.19M | Capitalization | 1.62B |
---|---|---|---|---|---|
Net income 2024 * | -194M | Net income 2025 * | -216M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 123 x |
P/E ratio 2024 * |
-9.19
x | P/E ratio 2025 * |
-8.85
x | Employees | 142 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.82% |
Latest transcript on Kura Oncology, Inc.
1 day | +0.76% | ||
1 week | -0.09% | ||
Current month | +1.19% | ||
1 month | -0.23% | ||
3 months | +49.06% | ||
6 months | +143.22% | ||
Current year | +48.33% |
Managers | Title | Age | Since |
---|---|---|---|
Troy Wilson
CEO | Chief Executive Officer | 55 | 14-08-21 |
Stephen Dale
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-08-24 |
Kathleen Ford
COO | Chief Operating Officer | 77 | 19-08-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 21-06-02 |
Faheem Hasnain
BRD | Director/Board Member | 65 | 15-04-26 |
Thomas Malley
BRD | Director/Board Member | 55 | 15-10-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.05% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 21.33 | +0.76% | 867,490 |
24-03-27 | 21.17 | +3.67% | 654,368 |
24-03-26 | 20.42 | -2.72% | 778,369 |
24-03-25 | 20.99 | -1.92% | 482,551 |
24-03-22 | 21.4 | +0.23% | 1,112,373 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.33% | 1.62B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |